Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 10.80 as of 2026-10-06T15:56:49.378Z.
Consensus retrieved: 2026-10-06T12:48:16.718Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:56:49.378Z.
Quote observation: 2026-10-06T15:55:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e377873a2157880dd21169cfa1e21286f4711b81b4878f64e5e393991bf66b3c
Forward PE Ratio (10.80) = Dated Quote Price ($13.99) / Consensus Forward EPS ($1.30)
FORWARD PE RATIO
10.80
SECTOR MEDIAN · HEALTHCARE
19.78
median of 173 covered companies
CURRENT VS SECTOR MEDIAN
-45.40%
vs the sector median at left
InMode Ltd.
Market Cap
$804.44M
Forward PE Ratio
10.80
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| InMode Ltd. (INMD) | $804.44M | 10.80 |
| Apnimed, Inc. (APMD)vs › | $802.84M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $798.82M | N/A |
| AdaptHealth Corp. (AHCO)vs › | $795.92M | N/A |
| Ardelyx, Inc. (ARDX)vs › | $815.71M | N/A |
| Geron Corporation (GERN)vs › | $789.07M | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $819.99M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $784.23M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $778.76M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $778.67M | N/A |
Trailing P/E
11.4
reported TTM EPS
Forward P/E
10.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.30 implies +5.7% EPS growth vs the reported trailing $1.23.
At the dated quote price of $13.99, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.30 | $1.27 – $1.31 | 3 | 10.8x |
| 2027-12-31 | $1.37 | $1.21 – $1.43 | 5 | 10.2x |
| 2028-12-31 | $1.45 | $1.17 – $1.77 | 5 | 9.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
